StockNews.com started coverage on shares of 22nd Century Group (NASDAQ:XXII – Free Report) in a report released on Wednesday. The brokerage issued a sell rating on the biotechnology company’s stock.
22nd Century Group Stock Performance
NASDAQ:XXII opened at $0.19 on Wednesday. The firm has a 50-day simple moving average of $0.44 and a 200-day simple moving average of $3.35. 22nd Century Group has a one year low of $0.15 and a one year high of $11.84. The firm has a market cap of $4.02 million, a P/E ratio of 0.00 and a beta of 1.39.
22nd Century Group (NASDAQ:XXII – Get Free Report) last issued its quarterly earnings data on Tuesday, August 13th. The biotechnology company reported ($0.36) EPS for the quarter. The business had revenue of $7.95 million during the quarter. 22nd Century Group had a negative return on equity of 380.39% and a negative net margin of 275.12%.
Hedge Funds Weigh In On 22nd Century Group
About 22nd Century Group
22nd Century Group, Inc, a tobacco products company, engages in the sale and distribution of its own proprietary new reduced nicotine tobacco products. The company offers reduced nicotine content tobacco plants and very low nicotine combustible cigarette products. It also provides contract manufacturing services for conventional combustible tobacco products for third-party brands.
Featured Articles
- Five stocks we like better than 22nd Century Group
- How to Start Investing in Real Estate
- The Outlook for Interest Rate Cuts Got Blown Out of the Water
- Do ETFs Pay Dividends? What You Need to Know
- 3 High-Risk, High-Reward Micro-Cap Stocks You Shouldn’t Ignore
- Stock Splits, Do They Really Impact Investors?
- 3 Bargain Stocks Positioned for Gains After Missing 2024’s Rally
Receive News & Ratings for 22nd Century Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for 22nd Century Group and related companies with MarketBeat.com's FREE daily email newsletter.